



Provider Notice

February 25, 2026

Insulin Discontinuation

This notice is to inform you that as of December 31, 2025, generic Novolog (insulin aspart) and generic Tresiba (insulin degludec) vials and pens were discontinued by the manufacturer.

In response, the Department of Healthcare and Family Services (HFS) has moved the brand name Humalog (insulin lispro) products to preferred status and will continue to maintain the generic insulin lispro and brand name Lantus (insulin glargine) products as preferred on the preferred drug list (PDL).

To avoid an interruption in treatment, pharmacies are encouraged to contact the patient's doctor to request a change to a preferred rapid-acting insulin agent. Pharmacies may continue to dispense generic insulin aspart until their stock is exhausted.

Click [here](#) to view the current CountyCare PDL.

Thank you for working with us to ensure that CountyCare members receive quality care at the right time and in the right setting. If you have any questions or would like additional information, please contact CountyCare Provider Services at countycareproviderservices@cookcountyhhs.org or your assigned Provider Relations Representative.